Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans

被引:40
作者
Ortoneda, M
Capilla, J
Pujol, I
Pastor, FJ
Mayayo, E
Fernandez-Ballart, J
Guarro, J
机构
[1] Univ Rovira & Virgili, Unitat Microbiol, Fac Med, E-43201 Reus, Spain
[2] Hosp Univ Sant Joan de Reus, Microbiol Lab, Reus, Spain
[3] Hosp Univ Sant Joan de Reus, Inst Estudis Avancats, Reus, Spain
[4] Hosp Univ Sant Joan de Reus, Fac Med, Unitat Microbiol, Reus, Spain
[5] Hosp Univ Tarragona Joan XXIII, Serv Patol, Tarragona, Spain
关键词
D O I
10.1093/jac/49.3.525
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We established a reproducible lethal disseminated infection by the opportunistic fungus Scedosporium prolificans in an immunosuppressed murine model. We compared the effectiveness of the combined administration of liposomal amphotericin B (LAMB) and granulocyte colony-stimulating factor (G-CSF) with that of either agent alone and with that of amphotericin B deoxycholate (AMB). LAMB + G-CSF and LAMB treatments improved survival significantly with respect to the untreated control. The mean survival times of these three groups were 13.2, 9.1 and 7.9 days, respectively. Culture results in terms of colony counts for samples of deep organs were lower in mice treated with the combined therapy, although differences were not significant. Combined LAMB + G-CSF therapy could be a promising approach for the treatment of disseminated infections of S. prolificans, although further studies are required to determine the most appropriate doses.
引用
收藏
页码:525 / 529
页数:5
相关论文
共 20 条
[1]   Deep infections caused by Scedosporium prolificans - A report on 16 cases in Spain and a review of the literature [J].
Berenguer, J ;
RodriguezTudela, JL ;
Richard, C ;
Alvarez, M ;
Sanz, MA ;
Gaztelurrutia, L ;
Ayats, J ;
MartinezSuarez, JV .
MEDICINE, 1997, 76 (04) :256-265
[2]   Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor [J].
Bouza, E ;
Munoz, P ;
Vega, L ;
RodriguezCreixems, M ;
Berenguer, J ;
Escudero, A .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (01) :192-193
[3]  
CANO J, 1992, J MED VET MYCOL, V30, P413
[4]  
Carrillo-Munoz A J, 1999, Rev Esp Quimioter, V12, P181
[5]   Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-γ [J].
Clemons, KV ;
Stevens, DA .
MEDICAL MYCOLOGY, 2000, 38 (03) :213-219
[6]   Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum [J].
Cuenca-Estrella, M ;
Ruiz-Díez, B ;
Martínez-Suárez, JV ;
Monzón, A ;
Rodríguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :149-151
[7]   GRANULOCYTE-COLONY-STIMULATING FACTOR - ROLE AND RELATIONSHIPS IN INFECTIOUS-DISEASES [J].
DALE, DC ;
LILES, WC ;
SUMMER, WR ;
NELSON, S .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :1061-1075
[8]  
de Hoog G.S., 2000, ATLAS CLIN FUNGI, VSecond
[9]  
Gosbell I. B., 1999, Clinical Microbiology and Infection, V5, P672, DOI 10.1111/j.1469-0691.1999.tb00513.x
[10]  
Graybill JR, 1997, J MED VET MYCOL, V35, P243